Ophthalmic Drugs Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Ophthalmic Drugs Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Anti-Inflammatory Drugs, Anti-Infection Drugs, Anti-Allergic Drugs, Anti-Glaucoma Drugs, Others) By Indication (Dry Eye, Eye Allergy, Glaucoma, Eye Infection, Others) By Product Type (OTC Drugs v/s Prescription Drugs) By Dosage Form (Gels, Ointments, Eye Solutions, Eye Drops, Tablets & Capsules) By Route of Administration (Topical, Ocular, Systemic) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) By Region & Competition, 2021-2031F
報告摘要
Market Overview
The global ophthalmic drugs market is projected to expand from USD 46.24 billion in 2025 to USD 63.43 billion by 2031, demonstrating a compound annual growth rate of 5.41%. These specialized pharmaceutical formulations are crucial for the diagnosis, treatment, and management of various eye conditions affecting the anterior and posterior segments, including glaucoma, dry eye disease, and retinal disorders. The market's main driver is the escalating global aging population, coupled with a rise in lifestyle-related illnesses such as diabetes, which substantially increase the risk of vision impairment. This rising incidence of eye diseases fuels a continuous demand for effective treatments, with over one billion people worldwide experiencing preventable or treatable sight loss in 2025, according to the International Agency for the Prevention of Blindness, underscoring the vital need for pharmacological solutions.
Nevertheless, the market faces a considerable hurdle in the form of the complex and expensive regulatory approval process for new ocular therapeutics. The development of drugs capable of effectively penetrating the eye's protective barriers demands substantial capital and extensive clinical trials to prove both safety and efficacy. Such stringent regulatory demands, combined with high R&D costs, present significant entry barriers that can slow the commercialization of new treatments and hinder overall market growth.
Market Driver
The primary market driver is the transformative rise of biologics and gene therapies, which are redefining treatment approaches from mere symptom management to interventions that modify the disease itself. This shift is evident in the swift adoption of advanced bispecific antibodies and innovative gene delivery systems, delivering superior efficacy and lasting benefits for retinal conditions. These cutting-edge therapeutics have a considerable market impact, commanding high prices and rapidly securing significant market share post-launch. For example, Roche's novel bispecific antibody Vabysmo generated 3.9 billion Swiss Francs in 2024 sales, as reported in January 2025, highlighting the strong clinical demand for advanced biologics. Similarly, Regeneron Pharmaceuticals' EYLEA franchise achieved $5.97 billion in U.S. net sales for 2024, reported in February 2025, further emphasizing the commercial strength of biological treatments globally.
Concurrently, the increasing prevalence of chronic and age-related ocular conditions, especially age-related macular degeneration (AMD) and diabetic retinopathy, significantly propels market expansion. With a growing global elderly population, the incidence of vision-impairing disorders is escalating, driving the need for ongoing pharmacological care and boosting the adoption of newly approved therapies. This heightened disease burden directly translates into strong patient demand for effective treatments, fostering a favorable climate for market growth, as exemplified by Astellas Pharma's Izervay capturing roughly 60% of new U.S. patient starts for geographic atrophy between October and November 2024, reported in February 2025, indicating a substantial unmet need.
Market Challenge
A significant challenge for the Global Ophthalmic Drugs Market is the demanding and costly regulatory approval process for new ocular therapies. Creating formulations that can effectively penetrate the eye's intricate structures, such as the blood-retina barrier, requires sophisticated drug delivery systems and extensive safety data. These strict requirements compel manufacturers to undertake lengthy clinical trials and make substantial initial financial investments even before a product reaches the approval phase. This formidable entry barrier disproportionately impacts smaller biotechnology companies, which often lack the financial resources to endure prolonged regulatory delays, thus decreasing market competition and slowing overall innovation.
This challenge is further compounded by the high likelihood of clinical failures, which constrains overall market expansion. Companies must absorb considerable sunk costs from unsuccessful drug candidates, deterring investment in potentially groundbreaking, yet riskier, treatments for posterior segment disorders. The inherent difficulty of this development path is reflected across the broader biopharmaceutical industry, directly influencing ophthalmic R&D strategies. In 2025, the Pharmaceutical Research and Manufacturers of America highlighted the extreme risk in drug development, noting that only 12% of new molecular entities entering clinical trials ultimately gain regulatory approval. This low success rate forces pharmaceutical companies to be highly selective, consequently limiting the pipeline of novel ophthalmic drugs and impeding market growth.
Market Trends
A key trend is the adoption of sustained-release ocular drug delivery systems, which are transforming the market by resolving the crucial issue of patient non-adherence to daily topical treatments. This involves the commercialization of minimally invasive, intracameral implants that ensure continuous therapeutic dosing for chronic conditions such as glaucoma, effectively stabilizing intraocular pressure without depending on patient compliance. The rapid market acceptance of these devices highlights a strong clinical demand for long-lasting, burden-reducing interventions. For instance, Glaukos Corporation's iDose TR, a prolonged-release intracameral implant, achieved approximately $40 million in net sales in the third quarter of 2025 alone, as reported in October 2025, showcasing the immediate commercial significance of this delivery innovation.
Concurrently, the introduction of pharmacological treatments for presbyopia is broadening the market's focus from managing pathology to enhancing lifestyle. This trend signifies a major shift where miotic eye drops are increasingly used as a non-invasive substitute for corrective lenses to address age-related near-vision loss, thereby accessing a large patient demographic seeking freedom from spectacles. Pharmaceutical companies are actively targeting this consumer-driven segment with direct engagement strategies to accelerate adoption. This demand is exemplified by Orasis Pharmaceuticals' direct-to-consumer campaigns, which generated over 1 million clicks to learn about Qlosi since its launch, as reported in November 2025, indicating substantial patient interest in this new therapeutic class.
Key Market Players
* Novartis AG
* AbbVie Inc.
* Bausch Health Companies Inc.
* Santen Pharmaceutical Co., Ltd.
* Regeneron Pharmaceuticals, Inc.
* Horizon Therapeutics plc
* Pfizer Inc.
* F. Hoffmann-La Roche Ltd.
* Ocular Therapeutix, Inc.
* Sun Pharmaceutical Industries Ltd.
Report Scope
In this report, the Global Ophthalmic Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Ophthalmic Drugs Market, By Drug Class
* Anti-Inflammatory Drugs
* Anti-Infection Drugs
* Anti-Allergic Drugs
* Anti-Glaucoma Drugs
* Others
# Ophthalmic Drugs Market, By Indication
* Dry Eye
* Eye Allergy
* Glaucoma
* Eye Infection
* Others
# Ophthalmic Drugs Market, By Product Type
* OTC Drugs
* Prescription Drugs
# Ophthalmic Drugs Market, By Dosage Form
* Gels
* Ointments
* Eye Solutions
* Eye Drops
* Tablets & Capsules
# Ophthalmic Drugs Market, By Route of Administration
* Topical
* Ocular
* Systemic
# Ophthalmic Drugs Market, By Distribution Channel
* Hospital Pharmacy
* Retail Pharmacy
* Online Pharmacy
# Ophthalmic Drugs Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Ophthalmic Drugs Market.
Available Customizations:
Global Ophthalmic Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Ophthalmic Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class (Anti-Inflammatory Drugs, Anti-Infection Drugs, Anti-Allergic Drugs, Anti-Glaucoma Drugs, Others)
5.2.2. By Indication (Dry Eye, Eye Allergy, Glaucoma, Eye Infection, Others)
5.2.3. By Product Type (OTC Drugs v/s Prescription Drugs)
5.2.4. By Dosage Form (Gels, Ointments, Eye Solutions, Eye Drops, Tablets & Capsules)
5.2.5. By Route of Administration (Topical, Ocular, Systemic)
5.2.6. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
5.2.7. By Region
5.2.8. By Company (2025)
5.3. Market Map
6. North America Ophthalmic Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Indication
6.2.3. By Product Type
6.2.4. By Dosage Form
6.2.5. By Route of Administration
6.2.6. By Distribution Channel
6.2.7. By Country
6.3. North America: Country Analysis
6.3.1. United States Ophthalmic Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Indication
6.3.1.2.3. By Product Type
6.3.1.2.4. By Dosage Form
6.3.1.2.5. By Route of Administration
6.3.1.2.6. By Distribution Channel
6.3.2. Canada Ophthalmic Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Indication
6.3.2.2.3. By Product Type
6.3.2.2.4. By Dosage Form
6.3.2.2.5. By Route of Administration
6.3.2.2.6. By Distribution Channel
6.3.3. Mexico Ophthalmic Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Indication
6.3.3.2.3. By Product Type
6.3.3.2.4. By Dosage Form
6.3.3.2.5. By Route of Administration
6.3.3.2.6. By Distribution Channel
7. Europe Ophthalmic Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Indication
7.2.3. By Product Type
7.2.4. By Dosage Form
7.2.5. By Route of Administration
7.2.6. By Distribution Channel
7.2.7. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Ophthalmic Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Indication
7.3.1.2.3. By Product Type
7.3.1.2.4. By Dosage Form
7.3.1.2.5. By Route of Administration
7.3.1.2.6. By Distribution Channel
7.3.2. France Ophthalmic Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Indication
7.3.2.2.3. By Product Type
7.3.2.2.4. By Dosage Form
7.3.2.2.5. By Route of Administration
7.3.2.2.6. By Distribution Channel
7.3.3. United Kingdom Ophthalmic Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Indication
7.3.3.2.3. By Product Type
7.3.3.2.4. By Dosage Form
7.3.3.2.5. By Route of Administration
7.3.3.2.6. By Distribution Channel
7.3.4. Italy Ophthalmic Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Class
7.3.4.2.2. By Indication
7.3.4.2.3. By Product Type
7.3.4.2.4. By Dosage Form
7.3.4.2.5. By Route of Administration
7.3.4.2.6. By Distribution Channel
7.3.5. Spain Ophthalmic Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Class
7.3.5.2.2. By Indication
7.3.5.2.3. By Product Type
7.3.5.2.4. By Dosage Form
7.3.5.2.5. By Route of Administration
7.3.5.2.6. By Distribution Channel
8. Asia Pacific Ophthalmic Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Indication
8.2.3. By Product Type
8.2.4. By Dosage Form
8.2.5. By Route of Administration
8.2.6. By Distribution Channel
8.2.7. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Ophthalmic Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Indication
8.3.1.2.3. By Product Type
8.3.1.2.4. By Dosage Form
8.3.1.2.5. By Route of Administration
8.3.1.2.6. By Distribution Channel
8.3.2. India Ophthalmic Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Indication
8.3.2.2.3. By Product Type
8.3.2.2.4. By Dosage Form
8.3.2.2.5. By Route of Administration
8.3.2.2.6. By Distribution Channel
8.3.3. Japan Ophthalmic Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Indication
8.3.3.2.3. By Product Type
8.3.3.2.4. By Dosage Form
8.3.3.2.5. By Route of Administration
8.3.3.2.6. By Distribution Channel
8.3.4. South Korea Ophthalmic Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Indication
8.3.4.2.3. By Product Type
8.3.4.2.4. By Dosage Form
8.3.4.2.5. By Route of Administration
8.3.4.2.6. By Distribution Channel
8.3.5. Australia Ophthalmic Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Indication
8.3.5.2.3. By Product Type
8.3.5.2.4. By Dosage Form
8.3.5.2.5. By Route of Administration
8.3.5.2.6. By Distribution Channel
9. Middle East & Africa Ophthalmic Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Indication
9.2.3. By Product Type
9.2.4. By Dosage Form
9.2.5. By Route of Administration
9.2.6. By Distribution Channel
9.2.7. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Ophthalmic Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Indication
9.3.1.2.3. By Product Type
9.3.1.2.4. By Dosage Form
9.3.1.2.5. By Route of Administration
9.3.1.2.6. By Distribution Channel
9.3.2. UAE Ophthalmic Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Indication
9.3.2.2.3. By Product Type
9.3.2.2.4. By Dosage Form
9.3.2.2.5. By Route of Administration
9.3.2.2.6. By Distribution Channel
9.3.3. South Africa Ophthalmic Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Indication
9.3.3.2.3. By Product Type
9.3.3.2.4. By Dosage Form
9.3.3.2.5. By Route of Administration
9.3.3.2.6. By Distribution Channel
10. South America Ophthalmic Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Indication
10.2.3. By Product Type
10.2.4. By Dosage Form
10.2.5. By Route of Administration
10.2.6. By Distribution Channel
10.2.7. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Ophthalmic Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Indication
10.3.1.2.3. By Product Type
10.3.1.2.4. By Dosage Form
10.3.1.2.5. By Route of Administration
10.3.1.2.6. By Distribution Channel
10.3.2. Colombia Ophthalmic Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Indication
10.3.2.2.3. By Product Type
10.3.2.2.4. By Dosage Form
10.3.2.2.5. By Route of Administration
10.3.2.2.6. By Distribution Channel
10.3.3. Argentina Ophthalmic Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Indication
10.3.3.2.3. By Product Type
10.3.3.2.4. By Dosage Form
10.3.3.2.5. By Route of Administration
10.3.3.2.6. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Ophthalmic Drugs Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Novartis AG
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. AbbVie Inc.
15.3. Bausch Health Companies Inc.
15.4. Santen Pharmaceutical Co., Ltd.
15.5. Regeneron Pharmaceuticals, Inc.
15.6. Horizon Therapeutics plc
15.7. Pfizer Inc.
15.8. F. Hoffmann-La Roche Ltd.
15.9. Ocular Therapeutix, Inc.
15.10. Sun Pharmaceutical Industries Ltd.
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們